WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsSophia Genetics SA (SOPH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BrightSpring Health Services, Inc. Common Stock generates 16608% more annual revenue ($12.91B vs $77.27M). BTSG leads profitability with a 1.5% profit margin vs -102.2%. BTSG earns a higher WallStSmart Score of 54/100 (C-).

BTSG

Buy

54

out of 100

Grade: C-

Growth: 6.7Profit: 4.5Value: 3.0Quality: 7.5
Piotroski: 5/9Altman Z: 2.62

SOPH

Avoid

26

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: -3.43
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BTSGSignificantly Overvalued (-78.4%)

Margin of Safety

-78.4%

Fair Value

$22.46

Current Price

$44.82

$22.36 premium

UndervaluedFair: $22.46Overvalued

Intrinsic value data unavailable for SOPH.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
29.3%8/10

Revenue surging 29.3% year-over-year

SOPH1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
22.4%8/10

Revenue surging 22.4% year-over-year

Areas to Watch

BTSG4 concerns · Avg: 3.3/10
EPS GrowthGrowth
3.4%4/10

3.4% earnings growth

Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

Profit MarginProfitability
1.5%3/10

1.5% margin — thin

Operating MarginProfitability
3.0%3/10

Operating margin of 3.0%

SOPH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$371.96M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.043/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.

Bull Case : SOPH

The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 22.4% demonstrates continued momentum.

Bear Case : BTSG

The primary concerns for BTSG are EPS Growth, Return on Equity, Profit Margin. A P/E of 90.2x leaves little room for execution misses. Thin 1.5% margins leave little buffer for downturns.

Bear Case : SOPH

The primary concerns for SOPH are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

BTSG carries more volatility with a beta of 2.33 — expect wider price swings.

BTSG is growing revenue faster at 29.3% — sustainability is the question.

BTSG generates stronger free cash flow (174M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BTSG scores higher overall (54/100 vs 26/100) and 29.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, specializing in meeting the intricate needs of a diverse patient population, including individuals with intellectual and developmental disabilities as well as those requiring rehabilitation. The company emphasizes personalized care solutions backed by a highly trained workforce, ensuring exceptional patient outcomes. BrightSpring's strategic investment in technology and commitment to quality enable it to thrive in the growing market for value-based care, making it well-positioned to capitalize on the ongoing evolution of the healthcare landscape.

Visit Website →

Sophia Genetics SA

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Sophia Genetics SA (SOPH) is a pioneering leader in data-driven medicine, focusing on advanced genomic and clinical data analytics that enhance patient outcomes. Utilizing cutting-edge machine learning algorithms, the company provides a comprehensive platform that aids hospitals and laboratories in interpreting complex genomic data, thus facilitating personalized treatment strategies, especially in oncology, rare diseases, and hereditary disorders. With a strong international footprint and strategic partnerships with premier healthcare organizations, Sophia Genetics is committed to transforming healthcare through precision medicine, solidifying its position as a front-runner in the genomics landscape.

Want to dig deeper into these stocks?